泛亚洲 adapted ESMO 临床实践指南:转移性食管癌患者的管理——JSMO-ESMO 倡议,获 CSCO、KSMO、MOS、SSO 和 TOS 认可
该指南由 ESMO 与 JSMO 发起,基于 2016 年 ESMO 食管癌指南,针对亚洲转移性食管癌患者的种族差异进行适应性调整。共识由日本、中国、韩国、马来西亚、新加坡和台湾地区的肿瘤学会专家共同达成,投票基于科学证据,独立于各国当前治疗实践及药物可及性与报销情况。
要点
- 本指南为 2016 年 ESMO 食管癌指南的泛亚洲适应性调整,聚焦转移性食管癌管理。
- 共识由日本、中国、韩国、马来西亚、新加坡和台湾地区的肿瘤学会专家共同达成。
- 投票基于科学证据,独立于各国当前治疗实践及药物可及性与报销情况。
核心结论
- 本指南代表了日本、中国、韩国、马来西亚、新加坡和台湾地区肿瘤学会专家在转移性食管癌治疗上达成的共识意见。
研究设计与样本
- ESMO 与 JSMO 于 2017 年 11 月 ESMO 亚洲会议决定召开特别指南会议,旨在将 2016 年 ESMO 指南根据亚洲转移性食管癌患者的种族差异进行适应性调整。
- 共识由代表日本(JSMO)、中国(CSCO)、韩国(KSMO)、马来西亚(MOS)、新加坡(SSO)和台湾地区(TOS)肿瘤学会的转移性食管癌治疗专家达成。
- 投票基于科学证据,独立于各参与亚洲国家当前的治疗实践以及药物可及性和报销情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
引用
- Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019. PMID: 30475943. doi:10.1093/annonc/mdy498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。